Where injections fit in the hip OA pathway

For many people with hip osteoarthritis, the most pressing question at the mid-point of their condition is not whether they will eventually need surgery — it is whether there is anything useful to try in the meantime. The answer, in the right clinical circumstances, is yes: intra-articular injections have a defined and evidence-supported role in managing hip OA symptoms during the window before surgical options become necessary.

That window corresponds broadly to early-to-mid stage disease — typically Kellgren–Lawrence grade 1 to 3, where joint-space narrowing and cartilage change are present but the joint has not fully collapsed. At this stage, pain and stiffness can be significantly limiting even though a hip replacement is not yet clinically indicated or appropriate.

Injections sit at the third stage of the four-stage management pathway: after conservative care — physiotherapy, weight management, activity modification, and simple analgesia — and before surgical consideration. They are not a substitute for that earlier stage, and they are not a structural cure. The goal is symptom control and functional maintenance; an injection cannot reverse cartilage loss or remodel bone.

Patient selection is central to this. Injections are most appropriate when conservative measures have reached a plateau but the criteria for surgery have not yet been met. Where surgery is clearly indicated and a patient is ready to proceed, further injections are not routinely recommended. A specialist assessment — with clinical examination and up-to-date imaging — is needed to establish the disease stage and determine which agent, if any, is appropriate.

Corticosteroids and the short window of relief

Among the available injection agents, corticosteroids carry the most robust short-term evidence for hip OA. A 2024 network meta-analysis published in Bone & Joint, drawing on 16 randomised controlled trials and 1,735 participants, confirmed that corticosteroid injection is significantly superior to placebo for both pain reduction and functional improvement at three months. No other single agent in that analysis matched this outcome at the same time-point.

The limitation is equally well-established: by six months, that advantage has largely disappeared. The evidence does not support corticosteroids as a means of sustained symptom control, and the six-month data in the same analysis show no statistically significant difference from placebo.

What corticosteroids do offer is speed. Relief typically begins within 24 to 72 hours of injection — making them the appropriate choice when a patient is experiencing an acute pain flare with significant joint swelling, or when a defined window of symptom control is needed while awaiting planned surgery. Used in this focused way, a single injection serves a clear clinical purpose.

Repeated injection is a different matter. Corticosteroids — commonly methylprednisolone or triamcinolone — carry a recognised risk of chondrotoxicity and tendon weakening when administered at short intervals. NHS commissioning guidance requires that patients are counselled explicitly about the short-term nature of benefit before proceeding. The injection manages symptoms within a defined window; it does not alter the underlying disease or slow cartilage loss.

Hyaluronic acid and why UK access varies

Hyaluronic acid (HA) — sometimes called viscosupplementation — occupies more contested ground than corticosteroids, and understanding why that is matters when patients encounter conflicting advice about it.

The formal guideline position is discouraging. Both NICE and OARSI, reviewing the available trial data, have concluded that HA for hip OA shows efficacy broadly comparable to placebo, and neither body recommends it for this joint on that basis. That assessment shapes NHS commissioning: HA injection into the hip is classified as off-label in the UK, and routine NHS access is not available. The contrast with knee OA is direct — HA carries regulatory approval for the knee, making it a standard NHS pathway option there but typically a private one for the hip.

The published evidence, however, is not as settled as the guideline summaries imply. A 2022 systematic review by Rampal et al. and multiple randomised controlled trials have reported meaningful reductions in pain and functional limitation in patients with moderate-grade hip OA, with some benefit lasting up to six months. The evidence picture is genuinely contested rather than simply thin.

One practical point is consistent across the literature: HA acts slowly, with effects building over several weeks rather than days. This makes it unsuitable for acute pain flares, where a faster-acting agent is more appropriate.

The gap between formal guideline positions and real-world clinical use — particularly in private MSK settings, where HA for the hip is applied selectively in appropriate patient profiles — is wider here than for almost any other joint injection. That gap reflects an unresolved evidence debate, not a clear clinical verdict either way.

PRP and emerging orthobiologics — what the evidence actually shows

PRP sits at the most clinically active edge of the current evidence debate for hip OA — and the data around it reward careful reading rather than headline summaries.

A 2024 systematic review by Almutairi et al. found PRP injections safe and effective for hip OA, with outcomes favourable compared to alternatives including HA and a potential duration of benefit extending to 6–12 months. The 2024 Bone & Joint network meta-analysis (16 RCTs, 1,735 participants) reinforced this, identifying the HA+PRP combination as substantially superior to placebo for functional outcomes at six months — a finding that outperformed corticosteroid monotherapy at that time-point.

A 2025 meta-analysis published in Frontiers in Bioengineering & Biotechnology adds a complication. Across 190 patients in two RCTs and one cohort study, adding HA to PRP was associated with significantly worse pain scores at three and twelve months compared to PRP alone, with no functional benefit at any follow-up interval. These results and the NMA findings are not directly comparable: the NMA benchmarked HA+PRP against placebo, whereas the 2025 analysis compared it head-to-head against PRP monotherapy. Neither study resolves whether combining agents is broadly advisable; together, they illustrate how heavily the answer depends on which comparison is being made.

A separate and practical limitation applies to PRP across all trials: no two clinics prepare it identically. Platelet concentration, activation method, and injection volume differ substantially between providers, which constrains how reliably any single trial result applies to another clinic's protocol. For a patient asking 'which PRP?', the honest answer is that it is currently clinic-dependent.

BMAC and MSC-based options carry a theoretical regenerative rationale, but the hip-specific evidence base is thin and more heterogeneous than the larger body of work in knee OA. No guideline body — NICE, OARSI, or otherwise — formally endorses PRP or other orthobiologics for hip OA. In practice, private MSK clinicians have moved ahead of the formal guidance, applying these agents selectively where the alternative is early surgical referral.

Two rules that apply to every hip injection

Regardless of which injection agent is chosen, two practical constraints apply across the board — one technical, one related to surgical timing.

Image guidance is not optional

The hip is a deep joint, sitting well below the surface and surrounded by substantial soft tissue. Blind injection — without real-time imaging — cannot reliably confirm that the needle has entered the joint space rather than the surrounding tissue. All intra-articular hip injections should be performed under ultrasound or fluoroscopic (X-ray) guidance to ensure accurate placement. Septic arthritis following hip injection is rare when aseptic technique is correctly applied; image guidance is part of what makes that technique reliable, not a precaution against a routine hazard.

The 90-day rule before hip replacement

A minimum of 90 days must elapse between any corticosteroid hip injection and elective total hip arthroplasty (THA). This is a surgical safety constraint: the 90-day interval is associated with a reduced risk of periprosthetic joint infection following replacement. It is not a preference or a guideline suggestion — it is a hard clinical parameter that affects treatment timing.

Patients should inform their surgical team of any injection received, because the interval is calculated from the injection date, not from the date of a surgical consultation. If surgery is already clearly indicated and the patient meets the criteria for arthroplasty, further injections are not recommended as a means of delaying that step.

Matching the right option to where you are

Three broad clinical situations tend to map reasonably well to the agents covered in this article — though none of them is a firm prescription, and individual circumstances always override generalisations.

Acute flare-up, or a defined bridge to planned surgery. Corticosteroid is the most appropriate starting point: fast onset, strong short-term evidence, and a clear role when the goal is pain control over a fixed window of weeks. It is not a repeat strategy, and the 90-day surgical interval must be factored into timing from the outset.

Moderate-grade hip OA where surgery is not yet indicated and acute flare is not the primary picture. Hyaluronic acid may offer a medium-term option, with some evidence of benefit up to six months in this group. Access on the NHS is restricted; this is typically a private pathway, and the slower onset makes it unsuitable for acute presentations.

A longer symptom-management window is the goal and the patient understands the evidence is still developing. PRP is the most relevant consideration here — with a potential benefit duration of 6–12 months in some studies — but preparation is not standardised across providers, and formal guideline endorsement has not followed clinical practice.

In all three situations, injection sits alongside physiotherapy-led conservative management, not instead of it. The evidence does not support using any of these agents as a substitute for structured rehabilitation.

Because early and mid-stage hip OA can look similar on imaging yet respond differently to injection, a specialist assessment of both symptoms and disease severity is more informative than grade alone when deciding which route is appropriate.